Mortality from lung cancer could be reduced substantially through early detection and the implementation of targeted approaches for chemoprevention and treatment of early stage cancers. We conducted the first study in collaboration with the Colorado Lung SPORE to prospectively evaluate methylation in sputum of a large panel of genes for their ability to predict lung cancer. This nested, case-control study of persons from the Colorado Cohort revealed that a panel of genes could predict incident lung cancer between 3 and 18 months prior to clinical diagnosis with both a sensitivity and specificity of 64%. This same marker panel is now being used to evaluate methylation in sputum from prevalent stage I lung cancer cases compared to a second cohort of high-risk smokers. Methylation of three or more genes of a seven-gene panel revealed a sensitivity of 75% and a specificity of 81%. Evaluation of additional candidate biomarkers has identified other promising genes for inclusion in the ultimate panel for early detection of lung cancer. These studies support advancing a methylation gene panel to full clinical validation as a tool for early detection. This will be accomplished through collaboration with the Colorado SPORE by first determining the optimal gene panel for distinguishing newly diagnosed stage I lung cancer from cancer-free smokers. We will then validate the performance of the ultimate gene panel for early detection of lung cancer using ACRIN, a prospective cohort of people at high risk for lung cancer within the National Lung Screening Trial who are randomized to lung cancer screening modalities. Through a nested, case-control design, the sensitivity, specificity, positive, and negative predictive values of this gene panel will be determined. A second major goal for this project is to collaborate closely with Project 1 in which the reversal of abnormal gene silencing is being tested as a therapeutic target for lung cancer. The strategy of using the demethylating agent 5-azacytidine and the histone deacetylase inhibitors, sodium phenylbutyrate or MS275 has shown promising responses in the treatment of myeloid malignancies. This therapy may also be effective in an adjuvant setting to prevent recurrence of cancer in resected stage I lung cancer patients. Through collaboration with Project 1, we will use gene methylation in sputum as a biomarker to predict therapeutic response and recurrence of lung cancer in resected stage I lung cancer patients receiving adjuvant treatment with demethylating agents. Relevance to Public Health: These studies should ultimately lead to the development of an approved diagnostic test for early detection of lung cancer. In addition, these studies should clearly impact how early stage lung cancer is managed by creating a molecular-based test to guide treatment decisions and provide biomarkers for monitoring the efficacy of demethylation therapy.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
United States
Zip Code
Kim, Jung-Hyun; Thimmulappa, Rajesh K; Kumar, Vineet et al. (2014) NRF2-mediated Notch pathway activation enhances hematopoietic reconstitution following myelosuppressive radiation. J Clin Invest 124:730-41
Ahuja, Nita; Easwaran, Hariharan; Baylin, Stephen B (2014) Harnessing the potential of epigenetic therapy to target solid tumors. J Clin Invest 124:56-63
Izumchenko, Evgeny; Chang, Xiaofei; Michailidi, Christina et al. (2014) The TGF?-miR200-MIG6 pathway orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitors. Cancer Res 74:3995-4005
Li, Huili; Chiappinelli, Katherine B; Guzzetta, Angela A et al. (2014) Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget 5:587-98
Wrangle, John; Machida, Emi Ota; Danilova, Ludmila et al. (2014) Functional identification of cancer-specific methylation of CDO1, HOXA9, and TAC1 for the diagnosis of lung cancer. Clin Cancer Res 20:1856-64
Wrangle, John; Wang, Wei; Koch, Alexander et al. (2013) Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine. Oncotarget 4:2067-79
Singh, Anju; Happel, Christine; Manna, Soumen K et al. (2013) Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis. J Clin Invest 123:2921-34
Rudin, Charles M; Brahmer, Julie R; Juergens, Rosalyn A et al. (2013) Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer. J Thorac Oncol 8:619-23
Reed, M D; Tellez, C S; Grimes, M J et al. (2013) Aerosolised 5-azacytidine suppresses tumour growth and reprogrammes the epigenome in an orthotopic lung cancer model. Br J Cancer 109:1775-81
Kim, James; Aftab, Blake T; Tang, Jean Y et al. (2013) Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell 23:23-34

Showing the most recent 10 out of 231 publications